Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urelumab and Rituximab in CLL/SLL
NCT02420938Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2015
- Primary completion
- Jul 2020
01
Overview
A Phase 2 trial of urelumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Planned start Jul 2015; status: withdrawn.
02
Drugs
urelumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02420938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420938.